Expion360 Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Expion360 Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.65M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.62M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.16M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.52M | Mar 30, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.16M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.58M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.29M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.65M | Mar 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.24M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($13.48M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($7.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.54M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($4.72M) | Mar 30, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.70M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($6.75M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($7.17M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.95M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.26M) | Mar 30, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $558.9K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $295.3K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $397.7K | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $270.1K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $58.0K | Mar 30, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.04M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $7.91M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $8.75M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.24M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.91M | Mar 30, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.15M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($9.56M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($5.53M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.47M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($3.90M) | Mar 30, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $20.2K | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $567.4K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $113.7K | Mar 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.07M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $9.11M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $11.91M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.70M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.53M | Mar 30, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $6.59M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $6.56M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.09M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.27M | Mar 30, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.54M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.52M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $5.35M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $11.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $2.26M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($1.38M) | Mar 30, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.81M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($34.58M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($21.10M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($13.64M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($6.10M) | Mar 30, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.97M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $547.6K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.93M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.20M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $773.2K | Mar 30, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.2K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $230.2K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $349.3K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $510.5K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.13M | Mar 30, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (108) | Mar 31, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (21) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (108) | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.78M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 2.10M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 69,230 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 6.80M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 4.30M | Mar 30, 2023 |